Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald Bunjes

Showing results (71-80 of 107) with videos related to

Pageof 11
Sort By:
Blood|July 2, 2002
Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell doseCesare Guglielmi, William Arcese, Francesco Dazzi, et al.
Bone Marrow Transplantation|June 1, 2021
Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMTJohanna Waidhauser, Myriam Labopin, Jordi Esteve, et al.
Blood|April 9, 2005
Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)Barbara Wassmann, Heike Pfeifer, Michael Stadler, et al.
Frontiers in Immunology|May 19, 2023
Risk factors and characteristics influencing humoral response to COVID-19 vaccination in patients after allogeneic stem cell transplantationMarie Luise Hütter-Krönke, Adela Neagoie, Igor Wolfgang Blau, et al.
Blood|June 10, 2010
Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 studyWolfgang A Bethge, Thoralf Lange, Christoph Meisner, et al.
Leukemia & Lymphoma|October 12, 2020
Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia - a study of the Acute Leukemia Working Party of the EBMTThomas Heinicke, Myriam Labopin, Emmanuelle Polge, et al.
Blood|June 12, 2004
Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)Laurent Garderet, Myriam Labopin, Norbert-Claude Gorin, et al.
Bone Marrow Transplantation|September 29, 2019
Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working PartyAbdul Hamid Bazarbachi, Rama Al Hamed, Myriam Labopin, et al.
Cancer|December 17, 2013
Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow TransplantationMoshe Yeshurun, Myriam Labopin, Didier Blaise, et al.
Blood|March 23, 2006
Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantationChristoph Schmid, Michael Schleuning, Rainer Schwerdtfeger, et al.
Pageof 11

Showing results (71-80 of 107) with videos related to

Sort By:
Pageof 11
Blood|July 2, 2002
Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell doseCesare Guglielmi, William Arcese, Francesco Dazzi, et al.
Bone Marrow Transplantation|June 1, 2021
Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMTJohanna Waidhauser, Myriam Labopin, Jordi Esteve, et al.
Blood|April 9, 2005
Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)Barbara Wassmann, Heike Pfeifer, Michael Stadler, et al.
Frontiers in Immunology|May 19, 2023
Risk factors and characteristics influencing humoral response to COVID-19 vaccination in patients after allogeneic stem cell transplantationMarie Luise Hütter-Krönke, Adela Neagoie, Igor Wolfgang Blau, et al.
Blood|June 10, 2010
Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 studyWolfgang A Bethge, Thoralf Lange, Christoph Meisner, et al.
Leukemia & Lymphoma|October 12, 2020
Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia - a study of the Acute Leukemia Working Party of the EBMTThomas Heinicke, Myriam Labopin, Emmanuelle Polge, et al.
Blood|June 12, 2004
Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)Laurent Garderet, Myriam Labopin, Norbert-Claude Gorin, et al.
Bone Marrow Transplantation|September 29, 2019
Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working PartyAbdul Hamid Bazarbachi, Rama Al Hamed, Myriam Labopin, et al.
Cancer|December 17, 2013
Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow TransplantationMoshe Yeshurun, Myriam Labopin, Didier Blaise, et al.
Blood|March 23, 2006
Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantationChristoph Schmid, Michael Schleuning, Rainer Schwerdtfeger, et al.
Pageof 11